1. ALLA AKTIER
  2. NYHETER
  3. ONCOPEPTIDES

Oncopeptides

Nyheter Oncopeptides Nyheter alla bolag

Invitation to presentation of the year-end report 2023

Stockholm – February 21, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the fourth quarter and the 2023 year-end report, at 08:00 (CET) on February 27, 2024. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on February 27 at 09:00 CET.

The presentation will be hosted by Sofia Heigis, CEO, together with Henrik Bergentoft, CFO. The webcast will be held in English and published on the website of Oncopeptides – www.oncopeptides.com – in conjunction with the start of the presentation.
 
Information for participants
If you wish to participate via webcast please use the link below.
https://ir.financialhearings.com/oncopeptides-q4-report-2023

If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=50048285

For more information, please contact:
David Augustsson, Director of Corporate Affairs, Oncopeptides AB (publ)
E-mail: david.augustsson@oncopeptides.com
Cell phone: +46 76 229 38 68

About Oncopeptides
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. 

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com. 

Attachments
Invitation to presentation of the year-end report 2023

Datum 2024-02-21, kl 08:30
Källa MFN
Bifogade filer
Invitation to presentation of the year-end report 2023
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!